Sanofi-Aventis

Wockhardt to Launch Generic Version of BPH Drug Uroxatral

The drug, with the generic name of alfuzosin, is used to treat enlarged prostate.

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 10mg extended release tablets of Alfuzosin hydrochloride, which is used in treatment of Benign Prostatic Hyperplasia or enlarged prostate. Alfuzosin is the generic name for the brand Uroxatral marketed in the United States by Sanofi-Aventis. Wockhardt is launching the product immediately.

Your rating: None Average: 5 (2 votes)
Syndicate content